Itraconazole SB 130mg Capsules (HPMC Cap Shell)
Itraconazole SB (Solubility-Boosted) 130mg — same CYP51 inhibitory mechanism as INFEXIN 100 and 200. The 'SB' designation refers to a solubility-enhanced formulation using supersaturation technology that delivers equivalent or superior bioavailability to standard itraconazole 200mg capsules at a lower stated dose. The 130mg SB dose is bioequivalent to conventional 200mg itraconazole in terms of AUC and Cmax, enabling equivalent clinical outcomes with a lower dose burden. HPMC shell ensures acid-independent dissolution.
Same indications as itraconazole 200mg — onychomycosis, tinea infections, vaginal candidiasis, aspergillosis, and systemic mycoses — but at the bioequivalent SB-enhanced 130mg dose. Particularly suitable for patients concerned about drug load or where lower-dose equivalence is preferred.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
INFEXIN SB 130 represents the next generation of itraconazole formulation — delivering bioequivalent drug exposure at a lower stated dose through pharmaceutical solubility enhancement. For dermatologists and gynaecologists who want to prescribe the most bioavailable itraconazole formulation available, INFEXIN SB 130 provides premium efficacy assurance.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.